The Certara Market Access Channel
By Certara Evidence & Access
The Certara Market Access ChannelAug 01, 2018
(4) Policy Briefing: A new agenda for CMS, the Biden White House, and a Democratic Congress
We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice.
In this episode, we're discussing the Biden administration's policy positions, the fate of Trump-era CMS proposals, and what the new majority in the 117th Congress will mean for the biopharma industry.
Your host for this week is Max Goldstein, Director of Business Development, speaking to Ulrich Neumann, Senior Director, Access and Commercial Strategy. For any questions on the topics discussed today, please contact ulrich.neumann@certara.com or download our latest whitepapers here: https://www.certara.com/evidence-access/us-managed-markets/key-trends-us-specialty/
(3) The Part B IPI Model
Experts on call
Ulrich Neumann, Sr. Director, US Access ulrich.neumann@certara.com
Additional notes:
- We referenced the Implications of Pricing on Innovation which is thoroughly discussed in this article by USC's Darius Lakdawalla
Lakdawalla, Darius N. 2018. "Economics of the Pharmaceutical Industry." Journal of Economic Literature, 56 (2): 397-449.
DOI: 10.1257/jel.20161327